Potential Best-in-Class Next Generation Anti-CD40L Antibody

Tegoprubart is a humanized IgG1 anti-CD40L antibody with high affinity for CD40L (also called CD154), a well-validated biological target with broad therapeutic potential. It was built around safety and engineered to maximize efficacy and half life.

Importantly, tegoprubart targets CD40L (also called CD154), not the CD40 receptor. Blocking CD40L inhibits both CD40 and CD11 costimulatory signaling pathways with the potential for better efficacy. Blocking CD40L also increases polarization of lymphocytes to Tregs, creating a more tolerogenic environment, which provides the potential for better efficacy. CD40L is more selectively expressed than the CD40 receptor, thus the potential for improved safety, as well as pharmacokinetic, pharmacodynamic, and dosing advantages.

Strong Safety and Pharmacokinetic Profile

Eledon Pharmaceuticals has completed a Phase 2a 12-week, open label, multiple ascending dose level study in subjects with ALS. Data from the study showed that tegoprubart successfully met the primary endpoint of safety and tolerability, with no serious or severe adverse events related to study drug, and adverse events being generally consistent with what is expected in a population of ALS participants. Importantly, there were no signs of platelet activation or thrombosis in the participants and anti-drug antibodies were present in less than 5 percent of samples, of which all were of low titer and did not impact tegoprubart drug levels.